Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

Application Note

Optimization of complement-dependent cytotoxicity assay on OncoSignature cell lines

Screening candidate mAbs for complement-dependent cytotoxicity (CDC) activity represents a crucial step in the development pipeline of successful therapeutics.

In this application note, we present how our complement-dependent cytotoxicity (CDC) assay offering can help drug screening efforts by leveraging our semi-automated screening platform and OncoSignature™ cell panel.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

Have a sales representative contact me

First Name

Last Name

Country

Email Address

Company

Zip / Postal Code

Business Phone

Role

Products and Services of Interest

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Optimization of complement-dependent cytotoxicity assay on OncoSignature cell lines

Download Application Note

Revvity Sites Globally

Login/Register here

Revvity web shop online account

Optimization of complement-dependent cytotoxicity assay on OncoSignature cell lines

To view the full content please answer a few questions

Download Resource